Tatton Consulting supported Sutton-based AI proteomics company Eliptica in its successful application to Advancing precision medicine: Round 2, which was awarded £696,335 by Innovate UK for the project AIPIR – Development of an advanced AI proteomic platform to identify, track and predict host response to solid tumour immunotherapies. The project’s total Innovate UK grant across all partners was £696,335.
About the funded R&D project
Solid tumour immunotherapies such as Keytruda work well in some patients and not others, and there is limited ability to predict which. The project develops an AI proteomic platform to identify, track and predict host response to these therapies. A reliable predictor would change prescribing decisions, sparing non-responders from ineffective treatment and its side effects.
Award details
- Total project grant: £696,335
- Of which to Eliptica: £664,385
- Competition: Advancing precision medicine: Round 2
- Competition year: 2023/24
- Project: AIPIR – Development of an advanced AI proteomic platform to identify, track and predict host response to solid tumour immunotherapies
- Sector: Oncology / proteomics
- UKRI project record: Gateway to Research, project 10085848
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title above are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
